|
February 10, 2012
|
| 11:58 EDT |  | GSK |
|
|
February 9, 2012
|
| 06:24 EDT |  | GSK |
|
|
February 8, 2012
|
| 07:33 EDT |  | GSK |
|
| 06:21 EDT | | GSK |
| theflyonthewall.com: | GSK initiate OTC launch of Xerclear in Europe: trade mames Zoviduo, Zovirax Duo |
 Subscribe for More Information :theflyonthewall.com |
|
|
February 7, 2012
|
| 11:19 EDT | | GSK |
| theflyonthewall.com: | GlaxoSmithKline CEO says priority clear, "to deliver rising dividend" | | Says bolt-on acquisitions possible but only if return on capital is better than stock buybacks. :theflyonthewall.com |
|
| 11:18 EDT | | GSK |
|
| 08:00 EDT | | GSK |
|
| 07:58 EDT | | GSK |
|
| 07:55 EDT | | GSK |
| theflyonthewall.com: | GlaxoSmithKline sees GBP1B-GBP2B in stock buybacks in 2012 | | During the year the company completed GBP2.2B of share repurchases as part of its long-term program. Based on current market conditions, the company is currently targeting repurchases of GBP1-2B shares in 2012. :theflyonthewall.com |
|
| 07:53 EDT | | GSK |
|
| 07:50 EDT |  | GSK |
|
|
February 6, 2012
|
| 08:33 EDT | | GSK |
|
| 07:27 EDT | | GSK |
| theflyonthewall.com: | GlaxoSmithKline R&D units in internal competition for funding, Telegraph says | | GlaxoSmithKline (GSK) should reveal how many of its Discovery Performance Units secured increased funding and how many will see a reduction at a presentation Tuesday, following a previously announced internal competition for GBP 1.1B of funds, reported The Telegraph. Reference Link :theflyonthewall.com |
|
|
February 2, 2012
|
| 06:00 EDT | | GSK |
| theflyonthewall.com: | Ligand Pharmaceuticals' Melphalan shows succesful results in Phase II trial | | Ligand Pharmaceuticals (LGND) provided results from the Phase II study of its Captisol-enabled, propylene glycol-free Melphalan program. The Phase II study was completed in late 2011 and compared the safety, tolerability and pharmacokinetic profiles of the PG-free Melphalan intravenous formulation and the current clinically-used intravenous formulation of melphalan, sold by GlaxoSmithKline (GSK) as Alkeran for Injection, for multiple myeloma patients undergoing autologous transplantation. The Captisol-enabled product is expected to allow for longer administration durations and slower infusion rates, potentially enabling a higher dose intensity of pre-transplant chemotherapy. The new PG-free Melphalan was bioequivalent to Alkeran per guidance requirements, while also demonstrating a marginally higher systemic drug exposure of the multiple myeloma patients. Based on the successful Phase II results, the follow-on Pivotal study will utilize a dosing regimen comparable to Alkeran. :theflyonthewall.com |
|
|
February 1, 2012
|
| 15:06 EDT | | GSK |
|
| 14:16 EDT | | GSK |
|
| 05:11 EDT | | GSK |
| theflyonthewall.com: | Prestige Brands Holdings completes purchase of 15 brands from GlaxoSmithKline |
Subscribe for More Information :theflyonthewall.com |
|
|
January 31, 2012
|
| 08:16 EDT | | GSK |
| theflyonthewall.com: | Glaxo, Lilly, Pfizer, others interested in MN Pharms stake, Businessweek says |
Subscribe for More Information :theflyonthewall.com |
|
|
January 30, 2012
|
| 16:00 EDT | | GSK |
| theflyonthewall.com: | The FDA Pediatric Advisory Committee to hold a meeting | | The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act, for Wyeth Pharma's Prevnar 13 Vaccine and GlaxosmithKline's Cervarix Vaccine in a meeting to be held in Gaithersburg, Maryland on January 31 at 9 am. Webcast Link :theflyonthewall.com |
|
| 05:35 EDT | | GSK |
| theflyonthewall.com: | News Corp.'s James Murdoch leaving GlaxoSmithKline board, Bloomberg reports | | News Corp.'s (NWSA) deputy COO James Murdoch is cutting some of his ties to London a and will leave the board of GlaxoSmithKline (GSK) after less than three years, Bloomberg reports. Reference Link :theflyonthewall.com |
|
